HLB Therapeutics (115450) 🔎 In-depth
KOSDAQ · Price as of 2026-08-06 · Updated 2026-08-09
Classified under wholesale by standard industry code, HLB Therapeutics actually houses two businesses in one company: cold-chain distribution of vaccines and pharmaceuticals, which makes up the mid-80% range of revenue and generates the cash, and, built on top of it, the development of dry-eye and brain-tumor drug candidates through a U.S. joint venture and a subsidiary. The losses stem not from distribution margin but from new-drug R&D spending. In April the company bought back part of its convertible bonds before maturity, reducing potential dilution, followed by a conversion-price adjustment in June and a first-quarter report in May. What stands out is that a real revenue base, five straight years of top-line growth, a narrowing operating loss each year and a P/B of 1.31x are strengths, while the fact that value hinges heavily on the outcome of its ophthalmology drug trials, that financing and share dilution may recur, and that first-quarter revenue contracted should be weighed equally.
This page organises public market and filing data for information purposes. It is not a recommendation to buy or sell, nor investment advice. Metrics labelled “forward” are our own unverified estimates. Please verify with the original DART filings and decide at your own responsibility.
30-second brief
Pulled directly from the computed values below — not a separately written opinion.
What do the SourceComputedEstimateReading tags mean?
Source filings and exchange data · Computed calculated from public data · Estimate our own unverified projection · Reading drafted automatically, then rule-checked. See AI & Automation.
Core valuation metric
This stock's effective sub-sector is “Distribution & Wholesale/Retail” (Retail, Consumer Goods & Food), a type typically read first through P/E.
Retail and wholesale businesses run on relatively simple buy-and-sell margins, with sales and profits flowing steadily along with consumer demand. That makes price-to-earnings (P/E) — the share price against the profits the company earns — the natural first lens.
Price against earnings alone becomes unstable when earnings swing. Reading it together with price against assets helps gauge the downside.
That said, the company is currently in a revenue-growth rather than a profit phase, so this metric alone offers only a limited read.
This note explains how each sector is typically valued and is educational context only, not investment advice.
At-a-glance assessment financial health · growth · profitability · valuation
- The most recent full-year net result was a loss.
- Revenue rose 26.6% year over year, and the pace is quickening (3-year trend: rising).
- Most recent quarter (Q1 2026) revenue was 13.3% lower than a year earlier.
- ROE is -6.1% (controlling-interest basis). It is below the sector average.
- Operating margin is -5.1%.
- A sector-metric and in-depth research verdict — see “Valuation vs peers” below for the basis.
Ownership & governance As of 2025-12-31
Largest shareholder HLB 7.94% (corporate)
Controlling bloc incl. related parties 12.72%
With the controlling bloc holding 13%, ownership is dispersed, leaving room for control-related or activist dynamics.
🔎 In-depth analysis Reading
HLB Therapeutics is grouped under wholesale by standard classification, but it actually holds two businesses in one company. The first is the foundation that genuinely earns the money: vaccine and pharmaceutical distribution, which accounts for the mid-80% range of revenue. Because vaccines must be kept continuously refrigerated, a cold chain (a low-temperature distribution network) is required, and this infrastructure serves as the company's cash cow. The second targets future value: new-drug development. Through the U.S. joint venture ReGenTree it develops RGN-259, a candidate for dry-eye disease and neurotrophic keratitis, and through the subsidiary Oblato it develops the brain-tumor candidate OKN-007. In other words, it earns revenue from distribution and, on top of that, advances ophthalmology drugs through the clinic, and the losses stem not from wholesale margin but from new-drug R&D spending. Valuation, too, only reveals the true business when distribution (revenue and margin) and the drugs (clinical stage) are viewed separately.
The latest close is ₩2,025 and the market capitalization is ₩179.4 billion. The price sits above its 20-day moving average (₩1,737) and below its 60-day moving average (₩2,302). Short-term and medium-term trends are diverging, so the direction is best read separately. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 54.8, a neutral level. The one-month change is -10.4%, the three-month change is -43.5%, and the position relative to the 52-week high is -49.1%. Relative strength versus the KOSDAQ is 34 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 33% of all stocks. Over the past three months it lagged the index by 12.4%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Because current earnings are in the red, a P/E (how many times the price is of one year's profit) cannot be computed, and valuation is read through P/B (how many times the price is of net assets) of 1.19x and P/S (how many times the price is of one year's revenue) of 3.26x. Book value per share (BPS) is ₩1,696 and loss per share (EPS) is -₩104. Profitability is still negative, with ROE (what percent is earned in a year on equity) of -6.1%, an operating margin of -5.1% and a net margin of -13.3%. The balance sheet is not overburdened, with a debt ratio (debt relative to equity) of 152%, and short-term capacity is ample at a current ratio (assets convertible to cash within a year versus debt due within a year) of 284%. Still, a P/B of 1.31x is not a heavy number for a loss-making stock; it is just above net assets. For a loss-stage biotech, a trailing-earnings yardstick makes cheap-versus-expensive hard to judge, and the fair value shifts greatly with how the clinical pipeline is valued, which must be read together. Rather than declaring the current P/B a burden, it is more accurate to read where the drug value and distribution margin are heading.
The top line is clearly growing. Revenue rose for five straight years, from ₩43.6 billion in 2021 to ₩69.6 billion in 2025 (about +12% a year), and 2025 in particular accelerated to +26.6% over the prior year. Even on the loss side, the direction of narrowing is distinct. The operating loss shrank nearly in half for two straight years, from -₩8.7 billion in 2023 to -₩7.6 billion in 2024 and -₩3.5 billion in 2025, and the net loss improved markedly from -₩22.8 billion in 2024 to -₩9.2 billion in 2025. The trend of the loss shrinking year by year is itself a real signal of improving profitability. That said, in the first quarter of 2026 revenue was ₩13.0 billion, down 13.3% year over year, and operating and net losses recurred; because vaccine distribution revenue can be lumpy depending on quarterly shipment timing, it is too early to conclude from one quarter that the top-line trend has broken. Since annual earnings are still in the red, this is not yet a stage for assigning a positive forward P/E, and there is no official company annual profit guidance. So the crux of this year's growth is not an earnings figure but two branches: whether the distribution top line keeps expanding and the losses keep shrinking, and whether the ophthalmology drug trials advance on top of that.
Recent disclosures cluster around financing, governance and clinical developments. In April 2026 there was a disclosure of buying back part of the previously issued convertible bonds (which can be converted into shares) before maturity, a move that reduces the possibility of future dilution from conversion. In June there was a disclosure adjusting the conversion price of the convertible bonds. When the conversion price is adjusted, the number of shares that can come from the same bonds may change, making it a variable to track alongside the financing and governance flow. In March there were an annual general meeting and an investor presentation (IR), and in May the first-quarter report was filed. On the drug side, the progress of RGN-259 driven by ReGenTree in the U.S. and the subsidiary Oblato's brain-tumor candidate are the main topics the company itself addresses, and confirming clinical progress through IR and disclosures is the key channel for tracking this stock.
Starting with the strengths, three stand out. First, vaccine distribution, which makes up the mid-80% range of revenue, is a real revenue foundation, so unlike a pure loss-making clinical stock there is a business base that brings in cash. Second, the direction of loss reduction is clear, with the top line growing for five straight years and the operating loss shrinking nearly in half each year. Third, at a P/B of 1.31x it is just above net assets for a loss-stage biotech, sitting far below pipeline-centered names in the same clinical group. On the other hand, things to examine are equally clear. The direction of value hinges heavily on the outcome of the ophthalmology drug trials, and trials are inherently an area where success and failure diverge; because funds keep flowing into new-drug R&D, financing such as convertible bonds and share dilution may recur. The first-quarter revenue contraction is also a reason to check the top-line trend on a quarterly basis. In short, this stock is strong when the distribution top line and margin improve and the ophthalmology trials advance, and weak when trials are delayed or additional financing becomes frequent. Since the price is not heavy relative to net assets, it is a stock to judge by weighing the upside momentum of the trials and the funding and loss check-points equally.
🔎 Valuation vs peers Inconclusive
Both clinical new-drug developers (pipeline-value-centered) and vaccine/bio operating companies are taken as the peer set, with a profitable pharmaceutical firm as a control. Since it is loss-making, the comparison uses P/B and business structure rather than P/E.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| HLB | 0.00x | 11.30x | -52.69% |
| SK Bioscience | 0.00x | 1.59x | -3.21% |
| Daewoong | 5.94x | 0.83x | 15.56% |
Because earnings are in the red, cheap-versus-expensive cannot be split by P/E, so it is viewed alongside a same-stage clinical biotech (HLB, P/B 15.95), a vaccine/bio operating company (SK bioscience, P/B 1.73), and a mature, already-profitable pharmaceutical firm (Daewoong, P/E 6x, P/B 0.89, ROE 15%). At a P/B of 1.51x the company sits far below the pipeline-centered name in the same group (HLB) and near the vaccine operator (SK bioscience), placing it in the middle ground between an expectation-laden clinical stock and a results-proven pharmaceutical firm. Still, both P/B and P/S assume a loss, so value cannot be pinned down on a trailing-earnings yardstick, and the direction of value depends on the company's official variables of distribution-margin improvement and U.S. clinical progress; at this point, Inconclusive is more appropriate than a firm verdict.
Price history Close · MA20 · MA60
The latest close is ₩2,025 and the market capitalization is ₩179.4 billion. The price sits above its 20-day moving average (₩1,737) and below its 60-day moving average (₩2,302). Short-term and medium-term trends are diverging, so the direction is best read separately. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 54.8, a neutral level. The one-month change is -10.4%, the three-month change is -43.5%, and the position relative to the 52-week high is -49.1%. Relative strength versus the KOSDAQ is 34 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 33% of all stocks. Over the past three months it lagged the index by 12.4%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -12.45% / 6M -4.66% / 12M -46.93%
Key metrics Computed vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 1.19x is above the sector median (0.62x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is -6.1%, below the sector average (2.0%). The operating margin is -5.1%. The debt ratio is 35.3%, so the financial structure is stable.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $36.9M | $38.6M | $48.9M | +26.63% ↑ faster |
| Operating profit | -$6.1M | -$5.4M | -$2.5M | — |
| Net profit | -$1.6M | -$16.0M | -$6.5M | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $30.6M | $33.8M | $36.9M | $38.6M | $48.9M |
| Operating profit | -$7.8M | -$5.5M | -$6.1M | -$5.4M | -$2.5M |
| Net profit | -$12.1M | -$8.0M | -$1.6M | -$16.0M | -$6.5M |
| Revenue CAGR | 4-yr avg 12.40% | ||||
Revenue rose 26.6% year over year (2023 ₩52.6 billion → 2024 ₩54.9 billion → 2025 ₩69.6 billion), and the three-year trend is 'rising'. The pace of growth also quickened from the prior year. Operating results are in the red, so a swing back to profit matters more than the growth rate here. Over the 5 years on record, revenue compound annual growth (CAGR) is 12.4%. The two-year revenue CAGR is 15.0%. In the most recent quarter (Q1 2026), revenue was 13.3% lower than the same period a year earlier.
Latest quarterly results Source Q1 2026 · vs year-ago
Technical indicators Computed
What stands out
- Revenue grew 26.6% year over year, a sign of growth.
Points to watch
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2026-04-01FilingDisclosure of buying back convertible bonds (including overseas convertible bonds) before maturityBuying back part of the previously issued convertible bonds before maturity reduces the possibility of future dilution from conversion into shares. However, since cash is used for the buyback, it is a burden on funding capacity. Source
- 2026-06-04FilingAdjustment of the convertible-bond conversion priceThe per-share price applied on conversion is adjusted; typically when the share price falls the conversion price drops, so more shares can come from the same bonds, a variable that raises the possibility of dilution. Source
- 2026-05-15EarningsFiled the first-quarter 2026 report (revenue ₩13.0 billion, continued operating and net losses)First-quarter revenue fell 13.3% year over year and losses continued, a check-point showing that the top-line growth trend can break on a quarterly basis. Source
- 2026-03-27FilingDisclosure of annual general meeting results (approval of financial statements, board composition, etc.)As the once-a-year vote on major agenda items, it is the reference point for confirming governance changes such as director appointments and articles of incorporation. Source
- 2026-03-25IRDisclosure of holding an investor presentation (IR)A venue where the company directly explains business status and clinical progress, a channel for confirming official outlook and plans. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| Core revenue mix (weight of cold-chain and vaccine distribution) | revenue | approx. 42.6% + approx. 41.8% | Confirmed | link |
| Clinical status of the core pipeline RGN-259 | — | RGN-259 3(SEER-3) 1 , 3 | Confirmed | link |
| 2025 annual revenue | ₩69,561,353,835 | — | Unverified | link |
| P/B | 1.51x | — | Unverified | link |
Recent filings Source
- 2026-06-09OwnershipOwnership-change filing
- 2026-06-05OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-04Disclosure
- 2026-06-02OwnershipOwnership-change filing
- 2026-05-15PeriodicQuarterly report
- 2026-04-21OwnershipOwnership-change filing
- 2026-04-01Convertible-bond issuance
- 2026-03-27Disclosure
- 2026-03-27Disclosure
- 2026-03-27Shareholders' meeting notice
- 2026-03-25Disclosure
- 2026-03-25Disclosure
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.